RxDoctor Payments Data

Daniel Kobrinski, DO

Hematology & Oncology · Neptune Beach, FLNPI 1255610473

Payments from drug & device makers

$1,910,858in general payments, 2019–2025

Across 357 payments — averaging $5352.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$888K
  • Incyte Corporation$436K
  • E.r. Squibb & Sons, L.L.C.$355K
  • Genentech, Inc.$223K
  • Adaptive Biotechnologies Corporation$3K
  • Epizyme, Inc.$1K
  • plus $4K from 54 others

What the payments were for

  • Consulting fees$2,60032%
  • Travel & lodging$83410%
  • Food & beverage$4,63257%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited9$888,304
Incyte Corporation50$436,289
E.r. Squibb & Sons, L.L.C.21$354,930
Genentech, Inc.24$223,279
Adaptive Biotechnologies Corporation2$2,600
Epizyme, Inc.2$1,044
Pfizer56$718
Novartis34$521
Johnson & Johnson(2 entities)18$347
AstraZeneca(2 entities)8$239
Foundation Medicine, Inc.5$213
Genentech USA, Inc.12$177
Takeda Pharmaceuticals U.S.A., Inc.4$159
AbbVie8$144
Daiichi Sankyo Inc.8$136
Medtronic1$135
GSK3$119
Sanofi8$112
Merck7$102
Eisai Inc.5$86
Bristol Myers Squibb5$85
Ipsen Biopharmaceuticals, Inc4$79
Beigene USA, Inc.3$61
Taiho Oncology, Inc.4$58
Alnylam Pharmaceuticals Inc.2$53
Tempus AI, Inc2$52
Astellas Pharma US Inc4$50
Acrotech Biopharma Inc.2$42
Lilly USA, LLC2$38
Rigel Pharmaceuticals, Inc.2$35
Menarini Silicon Biosystems, Inc.2$35
Array Biopharma Inc2$32
Gilead2$32
Bayer2$30
Dova Pharmaceuticals2$29
Coherus Oncology, Inc.1$29
Regeneron Healthcare Solutions, Inc.2$28
Tesaro, Inc.2$27
Global Blood Therapeutics, Inc.2$27
Stemline Therapeutics Inc.2$26
Aurobindo Pharma USA, Inc.2$25
Springworks Therapeutics, Inc.1$23
Fennec Pharmaceuticals, Inc.1$23
Mirati Therapeutics, Inc.1$22
Secura Bio, Inc.2$22
Tersera Therapeutics LLC1$21
Agios Pharmaceuticals, Inc.1$21
Octapharma USA, Inc.1$20
ADC Therapeutics America, Inc.1$20
Novocure Inc.1$19
Lexicon Pharmaceuticals, Inc.1$17
EMD Serono, Inc.1$16
Boehringer Ingelheim1$15
Jazz Pharmaceuticals Inc.1$15
TG Therapeutics, Inc.1$13
Kyowa Kirin, Inc.1$13
Morphosys, US Inc.1$13
Pharmaessentia USA Corporation1$12
ADMA Biomanufacturing LLC1$9
Heron Therapeutics, Inc.1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,910,858 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$4,090,756
Medicare patients
7,888
Services billed
254,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$165,104
CalquenceAcalabrutinib Maleate15$154,207
VenclextaVenetoclax12$138,985
XareltoRivaroxaban37$28,814
ValacyclovirValacyclovir Hcl46$1,478
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen47$1,169
Anastrozole50$1,083
Hydroxyurea27$747
Ondansetron OdtOndansetron34$592
Oxycodone Hcl15$529
Dexamethasone47$527
Prochlorperazine Maleate36$466
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$426
Ondansetron Hcl54$398
Acyclovir32$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$718$165,104204 claims
AstraZenecaCalquence$239$154,20715 claims
AbbVieVenclexta$144$138,98512 claims
Johnson & JohnsonXarelto$347$28,81437 claims
Lilly USA, LLCOlanzapine$38$27013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Neptune Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →